Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Response Assessment and Post–CAR T-Cell Therapy Management
Background CD19 chimeric antigen receptor-T (CAR T) cell therapy has dramatically improved the outcomes for pediatric and adult patients with short-term complete remission (CR) rates of approximately 90% in relapsed/refractory B-lineage acute lymphoblastic leukemia (ALL) and objective response rates (ORRs)…